SCHEMBL10104425

SCHEMBL10104425

Cc1cc(N2CC(C)NC(C)C2)cc(C(F)(F)F)c1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FFAR4 Q5NUL3 2/20 0.43
ADRB1 P08588 1/20 0.42
EIF2AK4 Q9P2K8 1/20 0.37
DPP4 P27487 1/20 0.36
PHGDH O43175 4/20 0.36
TGFBR1 P36897 1/20 0.35
ACVR1 Q04771 1/20 0.35
KCNH2 Q12809 1/20 0.35
NOTUM Q6P988 1/20 0.35
BRAF P15056 1/20 0.34
GHSR Q92847 2/20 0.33
CHRNB4 P30926 1/20 0.33
CHRNA3 P32297 1/20 0.33
NR2E1 Q9Y466 1/20 0.33
ALDH1A1 P00352 2/20 0.33
HTR3E A5X5Y0 1/20 0.33
HTR3B O95264 1/20 0.33
HTR1D P28221 1/20 0.33
HTR2C P28335 1/20 0.33
HTR3A P46098 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25745795 0.85 FFAR4 (0.45) FFAR4ADRB1DPP4PHGDHALDH1A1
SCHEMBL10104429 0.84 ADRB1 (0.50) FFAR4ADRB1DPP4PHGDHALDH1A1
SCHEMBL10104299 0.81 KDM4E (0.46) FFAR4ADRB1DPP4PHGDHBRAF
SCHEMBL24813391 0.78 FFAR4 (0.43) FFAR4ADRB1DPP4PHGDHALDH1A1
SCHEMBL23744579 0.77 NOTUM (0.45) EIF2AK4TGFBR1ACVR1KCNH2NOTUM
SCHEMBL23728111 0.77 NOTUM (0.45) EIF2AK4TGFBR1ACVR1KCNH2NOTUM
SCHEMBL17513742 0.77 NOTUM (0.45) EIF2AK4TGFBR1ACVR1KCNH2NOTUM
SCHEMBL23744578 0.77 NOTUM (0.45) EIF2AK4TGFBR1ACVR1KCNH2NOTUM
SCHEMBL12398720 0.75 ADRB1 (0.53) FFAR4ADRB1DPP4PHGDHALDH1A1
SCHEMBL10104274 0.74 ADRB1 (0.77) FFAR4ADRB1PHGDHALDH1A1HTR3E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8778929-B2 Substituted heteroaryl inhibitors of B-RAF BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2014-07-15 US disclosed
US-8653087-B2 Pyrido [5, 4-D] pyrimidines as cell proliferation inhibitors BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2014-02-18 US disclosed
US-20120094975-A1 PYRIDO [5, 4-D] PYRIMIDINES AS CELL PROLIFERATION INHIBITORS BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2012-04-19 US disclosed
US-20110312939-A1 NEW CHEMICAL COMPOUNDS BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2011-12-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110312939-A1 NEW CHEMICAL COMPOUNDS CCNA1, CCNT1, MKI67 FFAR4 4204/4885ADRB1 940/4885EIF2AK4 1724/4885
US-20120094975-A1 PYRIDO [5, 4-D] PYRIMIDINES AS CELL PROLIFERATION INHIBITORS CCNT1, CCNA1, CCND1 FFAR4 2848/4885ADRB1 1165/4885EIF2AK4 3093/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.